Mamangkey Jendri, Fadjri Corrina Lailatul, Mustopa Apon Zaenal, Suryanto Dwi, Puspa Hermana Nabila Swarna, Yanti Nur Arfa, Kusmiati Kusmiati, Irawan Herman, Hartanto Adrian, Adi Parman Rudia La Ode, Akmaliyah Rizna, Mendes Lucas William
Department of Biology Education, Faculty of Education and Teacher Training, Universitas Kristen Indonesia, Jl. Mayjen Sutoyo No. 2, Cawang, Jakarta Timur, 13630 Jakarta, Indonesia; Postdoctoral Fellow at Research Center for Genetic Engineering, Research Organization for Life Sciences and Environment, National Research and Innovation Agency (BRIN), KST Soekarno, Cibinong, Bogor, Indonesia.
Department of Biology, Faculty of Military Mathematics and Natural Sciences, Republic of Indonesia Defense University, Bogor, Indonesia.
J Genet Eng Biotechnol. 2025 Sep;23(3):100538. doi: 10.1016/j.jgeb.2025.100538. Epub 2025 Jul 18.
The ongoing quest for novel therapeutic agents has directed attention toward bioactive compounds derived from sponge-associated bacteria. This study focuses on sponge symbiont bacteria from the mangrove ecosystems in Tanjung Tiram, Southeast Sulawesi, which have not yet been reported for their potential antibacteria, anti-inflammatory, antioxidant, and anti-diabetic activities. The screening of marine bacterial isolates was performed using a series of assays: disc diffusion method to assess antibacterial activity, protein denaturation to assess anti-inflammatory properties, DPPH free radical scavenging to evaluate antioxidant capacity, and α-Glucosidase inhibition for anti-diabetic activity, followed by in silico validation. Two promising strains, identified through molecular techniques were designated as Oceanimonas sp. JM-AZM31 and Lysinibacillus fusiformis JM-AZM37. Initial bioactivity screening revealed significant potential: The bacterial isolates JM-AZM31 and JM-AZM37 demonstrated broad-spectrum antibacterial activity against both Gram-positive pathogens (Bacillus cereus, Staphylococcus aureus, Staphylococcus epidermidis) and Gram-negative pathogens (Escherichia coli, Salmonella typhimurium). JM-AZM31 exhibited an anti-inflammatory inhibition rate of 76.9 ± 2.90 %, antioxidant activity of 80.3 ± 1.02 %, and anti-diabetic activity of 84.9 ± 0.49 %. Similarly, JM-AZM37 showed anti-inflammatory activity of 71.6 ± 1.85 %, antioxidant activity of 76.9 ± 0.03 %, and anti-diabetic activity of 83.2 ± 1.27 %. Further analysis using GC-MS identified five significant compounds, which were examined through in silico molecular docking. Results indicated that n-hexadecanoic acid, DL-proline, 5-oxo-, and cis-vaccenic acid showed high binding affinities to specific therapeutic targets, suggesting strong potential as biotherapeutic agents. This current inquiry concentrates on the therapeutic potential of marine bacteria from mangrove ecosystems as a source of bioactive compounds, positioning Oceanimonas sp. JM-AZM31 and L. fusiformis JM-AZM37 as promising candidates for developing new biotherapeutic treatments.
对新型治疗药物的不断探索已将注意力转向源自海绵共生细菌的生物活性化合物。本研究聚焦于来自东南苏拉威西省丹戎提拉迈红树林生态系统的海绵共生细菌，其潜在的抗菌、抗炎、抗氧化和抗糖尿病活性尚未见报道。使用一系列测定方法对海洋细菌分离株进行筛选：采用纸片扩散法评估抗菌活性，蛋白质变性法评估抗炎特性，DPPH自由基清除法评估抗氧化能力，α-葡萄糖苷酶抑制法评估抗糖尿病活性，随后进行计算机模拟验证。通过分子技术鉴定出的两株有前景的菌株被命名为海洋单胞菌JM-AZM31和梭状赖氨酸芽孢杆菌JM-AZM37。初步生物活性筛选显示出显著潜力：细菌分离株JM-AZM31和JM-AZM37对革兰氏阳性病原体（蜡样芽孢杆菌、金黄色葡萄球菌、表皮葡萄球菌）和革兰氏阴性病原体（大肠杆菌、鼠伤寒沙门氏菌）均表现出广谱抗菌活性。JM-AZM31的抗炎抑制率为76.9±2.90%，抗氧化活性为80.3±1.02%，抗糖尿病活性为84.9±0.49%。同样，JM-AZM37的抗炎活性为71.6±1.85%，抗氧化活性为76.9±0.03%，抗糖尿病活性为83.2±1.27%。使用气相色谱-质谱联用仪（GC-MS）进行的进一步分析鉴定出五种重要化合物，并通过计算机模拟分子对接对其进行了研究。结果表明，正十六烷酸、DL-脯氨酸、5-氧代和顺式- vaccenic酸对特定治疗靶点表现出高结合亲和力，表明其作为生物治疗剂具有强大潜力。当前的这项研究集中于红树林生态系统海洋细菌作为生物活性化合物来源的治疗潜力，将海洋单胞菌JM-AZM31和梭状赖氨酸芽孢杆菌JM-AZM37定位为开发新型生物治疗方法的有前景候选菌株。
